Status:

COMPLETED

Masitinib Plus Docetaxel in Metastatic Castration-resistant Prostate Cancer

Lead Sponsor:

AB Science

Conditions:

Metastatic Castrate Resistant Prostate Cancer

Eligibility:

MALE

18+ years

Phase:

PHASE3

Brief Summary

Study of masitinib plus docetaxel as first-line chemotherapy in men with metastatic castration-resistant prostate cancer.

Detailed Description

The objective of this study is to evaluate the efficacy and safety of masitinib in combination with docetaxel and prednisone with respect to placebo in combination with docetaxel and prednisone in the...

Eligibility Criteria

Inclusion

  • Histologically or cytologically confirmed metastatic Castrate Resistant Prostate Cancer (medical or surgical castration: androgens deprivation by GnHR agonist or antagonist or patient with surgical castration; hormonal castration confirmed biologically (testosterone \< 0.5ng/ml) with one of the following criteria:
  • Pre-treated with abiraterone with documented progressive disease, OR
  • Indicated for initiating docetaxel treatment (e.g., widespread visceral disease or rapidly progressive disease).
  • Patient with evidence of progressive metastatic disease as assessed according to the Prostate Cancer Clinical Trials Working Group 2 (PCWG2) recommendations.
  • Patient with adequate organ function as per protocol

Exclusion

  • 1\. Patient who has been previously treated with chemotherapy.

Key Trial Info

Start Date :

September 1 2014

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 15 2020

Estimated Enrollment :

714 Patients enrolled

Trial Details

Trial ID

NCT03761225

Start Date

September 1 2014

End Date

December 15 2020

Last Update

September 29 2023

Active Locations (9)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 3 (9 locations)

1

Centre Hospitalier Universitaire de Sherbrooke

Sherbrooke, Canada, 13001

2

Polyclinique d'oncologie de Gentilly

Nancy, France, 54100

3

Sanjay Gandhi Post Graduate Institute of Medical Sciences

Lucknow, India, 226014

4

Centro di Riferimento Oncologico

Aviano, Italy, 33081